'Reassuring Data' for Two Multiple Sclerosis Meds in Pregnancy

Two studies report few complications from continuing ocrelizumab and natalizumab into pregnancy, with high live birth rates, a decline in elective abortions, and few major congenital abnormalities in newborns.

Related Keywords

Germany ,Spain ,Madrid ,German ,Celia Oreja Guevara ,Sandra Thiel ,Department Of Neurology ,University Hospital San Carlos ,Ruhr University Bochum ,First Trimester Screening Program ,Sclerosis Center ,Johns Hopkins School Of Medicine ,Research In Multiple Sclerosis ,European Committee For Treatment ,Josef Hospital ,European Committee ,Multiple Sclerosis ,Multiple Sclerosis Center ,German Multiple Sclerosis ,Pregnancy Registry ,Medscape Medical News ,Angie Child Jelin ,Johns Hopkins School ,Multiple Sclerosis Ms ,Us ,Pregnancy ,Postpartum ,Postnatal ,Uerperal ,Spontaneous Abortion ,Miscarriage ,Premature Birth ,Preterm Birth ,Irth Preterm ,First Trimester Pregnancy ,Birth ,Birth Defects ,Selective Abortion ,Multiple Sclerosis Relapse ,S Relapse ,Elapse Of Multiple Sclerosis ,Elapse Of Ms ,Newborn ,Neonate ,Europe ,European ,Hospitals ,Inpatient Care ,Multiple Scle ,